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Summary
Introduction: Extra-abdominal desmoid ﬁbromatosis (EADF) is a benign tumoral condition, clas-
sically managed by more or less radical and sometimes mutilating excision. This treatment
strategy is associated with a recurrence rate of nearly 50% according to various reports.
Hypothesis: EADF may show spontaneous stabilization over time.
Methods: A retrospective series of 26 cases of EADF managed by simple observation was studied
to assess spontaneous favorable evolution and identify possible factors impacting evolution.
Eleven cases were of primary EADF with no treatment or surgery, and 15 of recurrence after
surgery with no adjuvant treatment. MRI was the reference examination during follow-up.
Results: Twenty-four cases showed stabilization at a median 14months; there were no cases of
renewed evolution after stabilization. One primary tumor showed spontaneous regression, and
one recurrence still showed evolution at end of follow-up (23months). The sole factor impact-
ing potential for evolution was prior surgery. No radiologic or pathologic criteria of evolution
emerged from analysis.
Discussion: The present series, one of the largest dedicated to EADF managed by observation,
conﬁrmed recent literature ﬁndings: a conservative ‘‘wait-and-see’’ attitude is reasonable and
should be considered when large-scale resection would entail signiﬁcant functional or esthetic
impairment.
Level of evidence: Level IV, ret
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Extra-abdominal desmoid ﬁbromatosis (EADF) or aggres-
sive ﬁbromatosis is a rare tumor developing in the
musculo-aponeurotic structures. It is a low-grade soft tis-
sue tumor, which is systematically benign, without potential
malignancy or remote dissemination, but showing severe
local aggression and unpredictable evolution following
treatment. The reference attitude is extensive surgical
resection which, however, entails a risk of functional seque-
lae and signiﬁcant morbidity with a high rate of recurrence
even when resection extends to neighboring healthy tissue,
due to the inﬁltratory character of EADF [1—5].
The literature contains certain reports of short series
or occasional cases showing stabilization or regression of
non-operated primary or recurrent EADF managed by sim-
ple surveillance [3,6—8]. These reports encouraged us to try
simple wait-and-see surveillance in 26 of the EADF patients
managed in our center between 1989 and 2009.
The study sought to assess the reality and frequency
of spontaneous favorable evolution in the series, and to
identify predictive factors for evolution so as to improve
treatment strategy.
Material and methods
Material
The main inclusion criterion was conﬁrmed presence of all
anatomopathologic diagnostic signs of EADF on biopsy of
non-operated tumors or in the exeresis specimen in case
of recurrence after surgery:
• architectural criteria: tumor proliferation of ﬁbroblastic
or myoﬁbroblastic spindle cells, without areas of necrosis,
over a collagen ground rich in broad divergent bundles and
a few vessels surrounded by clear space. At the periphery
of the tumor, there may be small lymphoid islands. These
tumors are poorly contoured, invading fat and muscle;
• cytologic criteria: myoﬁbroblasts showing monomorphic
nuclei with between one and three small nucleoli and an
occasional mitosis.
Immunomarking: systematic exploration for smooth-
muscle actin, beta catenin, desmin, caldesmon, AE1, AE3,
EMA, PS100 and CD34 markers.
All included patients had been managed in the depart-
ment for EADF between 1989 and 2009.
Data were collected by systematic retrospective harvest-
ing of all historical, clinical and surgical records. Slides and
MRI slices were systematically reassessed.
All patients with complementary medical treatment
or radiochemotherapy (Glivec, Tamoxifen, anti-TNF alpha,
Indocid, etc.) were excluded.
No patients were lost to follow-up.
In all, 45 patients were treated for EADF, 26 of whom
(57%) underwent simple radioclinical surveillance. Two sub-
groups could be distinguished:• primary EADF (11 cases), with no surgical or medical treat-
ment;
• recurrent EADF (15 cases), undergoing surveillance after
one or more surgical operations: 14 of the 34 EADF
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patients operated on once or more during the study period
were cured; ﬁve recurrences were managed medically and
15 underwent simple radioclinical surveillance and were
included in the present study.
The choice between surgery and simple surveillance was
ased on the feasibility of sequela-free marginal resection.
ethods
urveillance comprised 6-monthly clinical examination and
ystematic MRI. MRI comprised sagittal, frontal and coronal
1, T2 and gadolinium-enhanced sequences. The evolution
riteria were tumor size on the longest axis and change in
umor signal.
Events were dated according to age on the day of initial
iagnosis. Surveillance of primary EADF was referenced by
he date of initial diagnosis and of recurrent EADF by the
ate of the diagnosis of recurrence.
Exeresis quality was assessed on the Union Internationale
ontre le Cancer (UICC) R classiﬁcation [9].
Data submitted to analysis concerned tumor location,
ize and MRI signal.
tatistical analysis
urvival was analyzed using the Kaplan-Meier method. The
vent considered was recurrence. Mean values were com-
ared by Fisher’s F-test; the signiﬁcance threshold was set
t 5%.
esults
eneral series characteristics
he series comprised 26 cases, with an M/F sex-ratio of 1/10
or primary EADF and 1/2 for recurrent EADF, or 1/3.3 for the
eries as a whole. In recurrent EADF, mean age on the day
f diagnosis of recurrence was 36 years (range, 14—67 years)
nd, in primary EADF, mean age on the day of diagnosis of
rimary tumor was 35.5 years (range, 21—73 years).
In primary tumor cases, discovery involved tumefaction
n all cases, with associated pain in four. In previously oper-
ted patients, recurrence was diagnosed on control MRI in
ll cases, with associated tumefaction in seven. There were
o histories of Gardner syndrome; trauma was noted in
even cases, but could not be formally linked to the tumoral
athology (shoulder, thigh or calf).
Surveillance found stabilization at a median 14months:
y month 14, tumor evolution had stabilized in half of the
atients; Fig. 1 shows the cumulative incidence curve for
volution arrest.Mean follow-up after case-by-case stabilization was
2.7months (range, 2—27months) in the primary EADF group
Figs. 2 and 3) and 19.1months (range, 1—80months) in the
ecurrence group. No surgery was required in any patient
uring surveillance.
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Figure 1 Cumulative incidence of arrest of evolution of extra-
abdominal desmoid ﬁbromatosis.
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Aigure 2 Follow-up and length of evolution of primary extra-
bdominal desmoid ﬁbromatosis.
esults in primary extra-abdominal desmoid
bromatosis
able 1 presents the characteristics of the primary EADF
atients. One patient (case 8) showed total regression at
months, and the others all showed arrest of evolution.
ean evolution to stabilization was 13.2months (range,
—30months) (Figs. 2 and 4). No patients showed renewed
rogression after stabilization.
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Table 1 Characteristics of patients with a primary extra-abdomi
Case Sex/age Location Date of diagnosis on
1st MRI
D
w
1 F/73 Shoulder 10/2004 03
2 F/21 Buttock 6/2008 12
3 F/28 Buttock 07/2008 12
4 F/28 Thigh 06/2006 08
5 F/27 Shoulder 10/2005 04
6 F/31 Hip 10/2006 5
7 M/34 Shoulder 5/2005 9
8 F/33 Hip 12/2005 06
9 F43 Thigh 06/2008 12
10 F/38 Shoulder 03/2008 09
11 F/35 Shoulder 02/2005 11
F: female; M: male.igure 3 Follow-up and length of evolution of recurrent
xtra-abdominal desmoid ﬁbromatosis.
esults in recurrent extra-abdominal desmoid
bromatosis
able 2 presents the characteristics of the recurrent EADF
atients. Mean evolution to stabilization was 20.9months
range, 5—53months) (Figs. 3 and 5).
Nine patients had undergone at least one revision
etween recurrence and initiation of surveillance. In case
f resection into healthy neighboring tissue (cases 15 and
0), recurrence stabilized at 24 and 41months, respectively.
n seven cases, the last resection involved contaminated
issue: six cases stabilized at a mean 29.3months (range,
—48months) and one (case 12) still showed evolution at
he time of writing, 36months after the last non-operated
ecurrence.
Six patients (two with resection into healthy and four into
ontaminated tissue) underwent simple radioclinical surveil-
ance after the ﬁrst recurrence, and stabilized at a mean
.3months (range, 5—19months).
nalysis of predictive factors for evolutivitynalysis of factors relevant to evolutivity found a signiﬁ-
ant time difference in evolution to stabilization between
rimary and recurrent EADF (P = 0.0417). Similarly, within
he recurrence group, patients reoperated on several times
nal desmoid ﬁbromatosis managed by simple observation.
ate of 1st MRI
ithout evolution
Evolution/tumor
growth duration (mo)
FU (mo)
/2007 Stable/29 20
/2008 Stable/6 2
/2008 Stable/6 2
/2007 Stable/11 17
/2008 Stable/30 8
/2008 Stable/19 7
/2006 Stable/16 25
/2006 Regressed/7 26
/2008 Stable/6 2
/2008 Stable/6 4
/2005 Stable/9 27
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Figure 4 Normal curve of the length of evolution of primary extra-abdominal desmoid ﬁbromatosis managed by surveillance.
t ext
tFigure 5 Normal curve of the length of evolution of recurren
showed signiﬁcantly longer evolution before stabilization
than those in whom recurrence was not managed by surgery
(P = 0.0203). On the other hand, no signiﬁcant time dif-
ference in evolution to stabilization emerged between
resection into healthy or contaminated tissue at last opera-
tion (P = 0.4099).
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Table 2 Characteristics of patients with recurrent extra-abdomin
Case Sex/age Location Date of 1st
operation
Number of
operations
Margin qua
at last
operation
12 F/18 Calf 05/2004 2 R2
13 F/42 Calf 1999 1 R1
14 F/42 Calf 1989 1 R1
15 F/44 Ankle 2004 2 R0
16 F/42 Calf 1999 1 R0
17 F/43 Knee 1993 2 R2
18 M/39 Thigh 2002 4 R2
19 F/23 Shoulder 03/2002 1 R0
20 M/30 Thigh 1994 3 R0
21 M/32 Calf 09/2007 1 R1
22 F/50 Forearm 2007 1 R2
23 M/51 Shoulder 1981 8 R2
24 F/14 Foot 1998 3 R2
25 F/16 Leg 1999 2 R1
26 F/43 Buttock 05/2007 2 R2
F: female; M: male; R0: extensive or radical exeresis; R1: marginal exera-abdominal desmoid ﬁbromatosis managed by surveillance.
Radiological analysis failed to identify any factors predic-
ive of evolution. In fact, radiology was consistently normal.
o bone invasion was found. Initial MRI at diagnosis found
esions with hypo- or iso-intense periphery on T1-weighted
mage. On T2, lesions were consistently hyperintense in the
enter. After gadolinium injection, there was systematic
al desmoid ﬁbromatosis.
lity Date of last
non-
operated
recurrence
Date of 1st
MRI without
evolution
Evolution/tumor
growth
duration (mo)
FU (mo)
02/2006 In growth
04/2007 06/2008 Stable/14 6
06/2000 03/2002 Stable/19 75
01/2007 01/2009 Stable/24 1
04/2007 12/2007 Stable/6 12
11/1997 04/2002 Stable/53 80
08/2007 06/2008 Stable/10 6
10/2004 03/2005 Stable/5 40
07/2003 01/2007 Stable/41 20
07/2008 01/2009 Stable/6 1
03/2008 09/2008 Stable/6 5
11/2004 01/2009 Stable/48 1
03/2004 03/2006 Stable/24 18
04/2002 04/2004 Stable/24 12
01/2008 02/2009 Stable/13 0
resis; R2: intralesional exeresis.
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Table 3 Extra-abdominal desmoid ﬁbromatosis MRI signal.
T1 T2
Hypo Iso Hyper Hypo Iso Hyper Gadolinium uptake
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Recurrence 12 3 0
Hypo: hypo-intense signal; iso: iso-intense signal; hyper: hyperint
nhancement of the lesion (Table 3). On follow-up MRI, new
eadings found no change in signal intensity in a given tumor.
umor size was very variable, independently of location and
volutivity.
Anatomopathology found no differences in architecture
etween primary and recurrent tumors. On immunohisto-
hemistry, smooth-muscle actin and beta catenin muscle
arkers were consistently positive in the periphery, and
esmin, caldesmon, AE1, AE3, EMA, PS100 and CD34 con-
istently negative.
iscussion
esmoid tumors are notorious for local recurrence after sur-
ical treatment, at a rate of 19% to 77%, depending on the
eport [1,10—15]. The present study shows initially strong
volutivity, whether spontaneous or secondary to surgical
ggression, which subsequently resolves in most cases.
The present study analyzed evolution in terms of tumor
ize on MRI. In the literature, MRI is the reference examina-
ion in EADF surveillance, optimally detailing the relation
o neurovascular structures and enabling objective and
eproductible measurement. There are, however, difﬁcul-
ies inherent to the measurement of a lesion the contours
f which may be fuzzy due to its inﬁltratory character. Dat-
ng is based on the date of the initial radiological diagnosis,
hich fails to take account of the interval of occult devel-
pment but does provide the physician with a reference for
ime of evolution from initial diagnosis.
There are many reports of incidental cases or series
howing tumor regression or stabilization. Rock et al. [1]
eported a series of 68 recurrent desmoid tumors man-
ged by surveillance: 60 had ceased to evolve at a mean
.1 years’ FU, and six had regressed; only two continued
o evolve. Lewis et al. [2] reported on 15 patients with
esmoid tumor that was non-excisable without amputation
nd was managed medically (chemotherapy, hormone ther-
py, NSAID) or by radiotherapy: nine tumors stabilized, and
wo regressed. Dalén et al. [6] reported some cases of spon-
aneous regression at more than 20 years in non-reoperated
ecurrent tumor. The main limitation of these studies was
hat they reported only recurrent tumors, known from the
iterature to show strong evolutive potential following sur-
ical aggression. Chatelard et al. [8] and Pignatti et al. [3],
onversely, reported a case of primary EADF that was sta-
le on long-term FU. Recently, Gouin et al. [7] performed
prospective study of a cohort of 17 primitive or recur-
ent EADF patients: 12 showed arrested tumor growth and
hree showed objective regression on MRI; there were no
ases of renewed evolution after regression or stabiliza-
ion. Likewise, Bonvalot et al. [15] reported 11 cases of
e
m
n
o0 11 11
0 15 15
signal.
ADF managed by surveillance in a series of 112 patients
anaged in their center: only three cases showed progres-
ion at 3 years’ FU. Fiore et al. [16], in a multicenter study
ncluding 83 cases of primary or recurrent desmoid ﬁbro-
atosis managed by surveillance and 59 managed medically
chemotherapy, hormone therapy), reported arrested evo-
ution in 49.9% of tumors managed by surveillance versus
8.6% of those managed medically at 5 years’ FU (P = 0.3).
In the present study, stabilization was at a median
4months. There was, however, a signiﬁcant difference
n evolution time between primary and recurrent EADF
P = 0.0417). Gouin et al. [7] reported a mean 10months’
volution (range, 0—36months), with no difference between
rimary and recurrent tumors. The evolutive potential of
ADF thus seems to be limited after 36months.
In the present study, surgery appeared as an aggravat-
ng factor for tumor evolution duration. In Bonvalot et al.’s
eries [15], at 3 years 44% of operated tumors showed
rowth, versus 68% of those managed by simple surveillance;
he authors concluded that there was a non-signiﬁcant
P = 0.07) trend towards better evolution in non-operated
han operated tumors, as conﬁrmed by the present ﬁnd-
ngs. Fiore et al. [16], on the other hand, reported identical
esults for primary and previously operated tumors, and
heir multivariate analysis disclosed no predictive factors
or evolution.
In the present study, resection margin quality in recur-
ence surgery did not appear as a predictive factor for
volution. For Bonvalot et al. [15], on the other hand,
rognosis for surgical treatment correlated strongly with
esection margin quality and with tumor location; for certain
atients, they therefore recommend simple surveillance for
period of months, and that surgery, when performed,
hould extend into healthy tissue. Even so, their ﬁndings
re open to discussion: two other studies, as well as the
resent, reported no link between resection margin quality
nd recurrence potential [4,8]. These various studies, how-
ver, are difﬁcult to compare, as the deﬁnition of margins
as not reproductible.
A conservative attitude is thus reasonable and may be
onsidered when extensive resection cannot be performed
ithout signiﬁcant functional or esthetic impact. While the
iterature still considers extensive resection to be the most
ffective form of treatment, the associated recurrence rate
s non-negligible [1,10—14], mainly within 2 years of surgery
1—3,5,6]. Surgery also entails a signiﬁcant risk of func-
ional and esthetic sequelae when resection aims to be
xtensive, as recommended by Leithner et al. [17] in their
eta-analysis. The morbidity associated with surgery is non-
egligible, and many series have reported amputation [1,7]
r severe aftereffects [6]; moreover, amputation does not
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always prevent recurrence [1,7,8]. Morbidity, furthermore,
increases the rate of revision surgery for recurrence. The
associated mortality rate, however, remains less than 1%
[1].
Thus, the high rate of recurrence, even after resection
into healthy margins, combined with signiﬁcant morbimor-
tality and a non-negligible risk of sequelae point to the
option of surgical abstention in favor of clinical and radio-
logical surveillance. Surgical resection should be envisaged
only if it can be complete.
In the present anatomopathological study, EADF always
showed the same positive and negative markers. No histo-
logic factors predictive of evolutivity emerged. There are,
moreover, no studies in the literature on this issue.
Finally, MRI likewise found no factors predictive of evo-
lutivity. Nakayama et al. [18] reported that three of the
seven patients managed by MRI surveillance showed a sig-
niﬁcantly reduced signal on T2-weighted images. Likewise,
Vandefenne et al. [19] reported that signal hyperintensity
on T2-weighted images was initially heterogeneous, then
diminished over tumor evolution, reﬂecting the reduction
in tumor cellularity and collagen density. Gouin et al. [7]
reported qualitative change in signal in some cases, with
reduced hypersignal in T2 and the appearance of hyposignal
areas. Castellazzi et al. [20] analyzed 18 desmoid tumors
managed by surveillance and 29 managed medically, to
determine the correlation between tumor size, MRI signal
and evolution of aggressive ﬁbromatosis: size was stable
in 79% of medically managed tumors and in 82% of those
managed by surveillance. The initial signal was generally
intense in tumors in which size was stable or reduced. The
MRI signal of a given tumor, however, was generally sta-
ble over time, whatever the initial signal or size. Change
in size did not correlate with initial signal. Reduction in
size associated with reduction in signal was found in only
three of the treated tumors. The authors concluded that
tumor behavior cannot be predicted from the MRI sig-
nal.
Conclusion
EADF is a tumor that can stabilize spontaneously over
time. The present study conﬁrms that simple observa-
tion is a treatment option that can always be considered,
being non-invasive, with low associated morbidity and sat-
isfactory results. Stabilization was at a median 14months.
After diagnosis of EADF, if the tumor has no major
functional impact and is not compressing neurovascular
structures, surveillance is recommended, using clinical
examination and 6-monthly MRI to assess spontaneous evo-
lution before considering any other treatment. To date,
no prognostic factors for tumor evolution have emerged.
However, recurrence after surgery would seem to be asso-
ciated with greater evolutivity than found in primary
tumor.Conﬂict of interest statement
None.
[889
eferences
[1] Rock MG, Pritchard DJ, Reiman HM, Soule EH, Brewster
RC. Extra-abdominal desmoid tumors. J Bone Joint Surg Am
1984;66:1369—74.
[2] Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The
enigma of desmoid tumors. Ann Surg 1999;229(6):866—73.
[3] Pignatti G, Barbanti-Brodano G, Ferrari D, Gherlinzoni F,
Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor.
A study of 83 cases. Clin Orthop 2000;375:207—13.
[4] Gronchi PG, Casali L, Mariani S, Lo Vullo M, Colecchia L, Lozza
R, et al. Quality of surgery and outcome in extra-abdominal
aggressive ﬁbromatosis: a series of patients surgically treated
at a single institution. J Clin Oncol 2003;21:1390—7.
[5] Merchant NB, Lewis JJ, Woodruff JM, et al. Extremity and trunk
desmoid tumors: a multifactorial analysis of outcome. Cancer
1999;86:2045—52.
[6] Dalén BPM, Bergh PM, Gunterberg BU. Desmoid tumors: a clin-
ical review of 30 patients with more than 20 years’ follow-up.
Acta Orthop Scand 2003;74:455—9.
[7] Gouin F, Tesson A, Bertrand-Vasseur A, Cassagnau E, Rolland F.
Étude de la croissance tumorale des tumeurs desmoïdes extra-
abdominales primitives ou récidivées non opérées. Rev Chir
Orthop 2007;93:546—54.
[8] Chatelard PA, Gilly FN, Carret JP, Vauzelle JL, Brunat M,
Baillon G, et al. Tumeurs desmoïdes extra-abdominales, indi-
cations thérapeutiques à propos de 28 cas. Acta Orthop Belg
1991;57:227—33.
[9] Sobin LH, Wittekind C.Tumor of bone and soft tissues. R classi-
ﬁcation. TNM classiﬁcation of malignant tumors UICC. 6th ed.
New York: Wiley Liss; 2002. p. p110.
10] Musgrove JE, McDonald JR. Extra-abdominal desmoid tumors.
Their differential diagnosis and treatment. Arch Pathol
1948;45:513—40.
11] Hunt R, Morgan H, Ackerman L. Principles in the management
of extra-abdominal desmoids. Cancer 1960;13:825—36.
12] Enzinger FM, Shiraki M. Musculo-aponeurotic ﬁbromatosis of
the shoulder girdle (extra-abdominal desmoid). Analysis of
thirty cases followed up for ten or more years. Cancer
1967;20:1131—40.
13] Das Gupta TK, Brasﬁeld RD, O’Hara J. Extra-abdominal
desmoids. A clinicopathological study. Ann Surg
1968;170:109—21.
14] Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid
tumors of the trunk and extremity. Cancer 1993;72:1637—41.
15] Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G,
Oberlin O, et al. Extra-abdominal primary ﬁbromatosis: aggres-
sive management could be avoided in a subgroup of patients.
Eur J Surg Oncol 2008;34:462—8.
16] Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux
C, et al. Desmoid-type ﬁbromatosis: a front line conservative
approach to select patient for surgical treatment. Ann Surg
Oncol 2009;16-9:2587—93.
17] Leithner A, Gapp M, Leithner K, Roman R, Krippl P, Beham A,
et al. Margins in extra-abdominal desmoid tumors: a compara-
tive analysis. J Surg Oncol 2004;86:152—6.
18] Nakayama T, Tsuboyama T, Toghuchida J, Hosaka T, Nakamura
T. Natural course of desmoid-type ﬁbromatosis. J Orthop Sci
2008;13:51—5.
19] Vandevenne JE, De Schepper AM, De Beuckeleer L, Lackman
RD. Desmoid tumors and current status of management. Orthop
Clin North Am 2006;37:53—63.
20] Castellazzi G, Vanel D, Le Cesne A, Le Pechoux C, Caillet H,
Perona F, et al. Can the MRI signal of aggressive ﬁbromatosis
be used to predict its behavior? Eur J Radiol 2009;69:222—9.
